NEO Neogenomics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NEO

Price (delayed)

$14.11

Market cap

$1.84B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.76

Enterprise value

$2.1B

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 91
Relative Valuation: Rel. Valuation: 20
Relative Profitability: Rel. Profitability: 25

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose ...

Highlights
The quick ratio has soared by 104% YoY and by 2.8% from the previous quarter
NEO's debt is down by 32% YoY
The net income has contracted by 28% YoY but it has grown by 8% from the previous quarter
The company's EPS fell by 25% YoY but it rose by 10% QoQ
The equity is down by 7% year-on-year
The gross margin has contracted by 2.5% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: https://neogenomics.com/
Peers: RDNT DGX LH

Key stats

What are the main financial stats of NEO

NEO stock price

How has the Neogenomics stock price performed over time
Intraday
0%
1 week
-6.93%
1 month
26.55%
1 year
94.35%
YTD
19.98%
QTD
-3.29%

Financial performance

How have Neogenomics's revenue and profit performed over time
Revenue
$745.97M
Gross profit
$321.91M
Operating income
-$106.3M
Net income
-$99.21M
Gross margin
43.2%
Net margin
-13.3%
The net income has contracted by 28% YoY but it has grown by 8% from the previous quarter
The company's operating income fell by 19% YoY but it rose by 8% QoQ
NEO's net margin is down by 16% YoY but it is up by 11% QoQ
Neogenomics's operating margin has increased by 11% from the previous quarter but it has decreased by 7% YoY

Price vs fundamentals

How does NEO's price correlate with its fundamentals

Growth

What is Neogenomics's growth rate over time

Valuation

What is Neogenomics stock price valuation
NEO P/E details
P/E
N/A
P/B
2.21
P/S
2.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.81
The company's EPS fell by 25% YoY but it rose by 10% QoQ
The price to book (P/B) is 70% more than the last 4 quarters average of 1.3 and 16% more than the 5-year quarterly average of 1.9
The equity is down by 7% year-on-year
The price to sales (P/S) is 63% higher than the last 4 quarters average of 1.5 but 28% lower than the 5-year quarterly average of 3.4
The revenue rose by 11% YoY and by 2.6% QoQ

Efficiency

How efficient is Neogenomics business performance
The return on assets has dropped by 50% year-on-year but it rose by 4% since the previous quarter
NEO's ROIC is down by 39% year-on-year but it is up by 7% since the previous quarter
The return on equity has declined by 37% year-on-year but it has increased by 6% since the previous quarter
The company's return on sales fell by 24% YoY but it rose by 9% QoQ

Dividends

What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NEO.

Financial health

How did Neogenomics financials performed over time
The total assets is 160% greater than the total liabilities
NEO's current ratio has soared by 116% YoY and by 3.8% from the previous quarter
The quick ratio has soared by 104% YoY and by 2.8% from the previous quarter
NEO's debt is 51% lower than its equity
NEO's debt is down by 32% YoY
The debt to equity has declined by 28% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.